News
Better International ETF: iShares' IXUS vs. Schwab's SCHE
The Schwab Emerging Markets Equity ETF (NYSEMKT:SCHE) and the iShares Core MSCI Total International Stock ETF (NASDAQ:IXUS) differ most in geographic reach, recent performance, and sector makeup
Investment Accounts for Kids
In this podcast, Motley Fool personal finance expert Robert Brokamp discusses the pros and cons of five of the most common options, including the new Trump accounts.
Also in this episode:
To catch
Warren Buffett Hit the Buy Button for $965,291,328 Late Last Year. Berkshire Now Owns Nearly 9.3% of This Leading Insurer.
Warren Buffett was apparently pretty bearish on the stock market late last year. The company he led as CEO until year end, Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B), was holding a record amount
Rule Breaker Investing Pet Peeves, Vol. 9
This edition of Rule Breaker Investing digs in on:
To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. When you're ready to invest, check out this top 10
EQS-Adhoc: Beiersdorf Aktiengesellschaft: Guidance 2026 –– New Share Buyback Program
StealthGas (GASS) Q4 2025 Earnings Call Transcript
Image source: The Motley Fool.
Monday, March 2, 2026 at 10 a.m. ET
Need a quote from a Motley Fool analyst? Email [email protected]
Source Fool.com
Buying This 1 Pharmaceutical Stock Today Could Make You a Multimillionaire Retiree
Over the past decade, Eli Lilly (NYSE: LLY) has produced amazing returns, becoming the largest healthcare stock in the world in the process -- and the first to hit a $1 trillion valuation. Lilly may
CoreWeave: After Dropping 18%, Is It a Stock to Avoid or Once-in-a-Decade Buying Opportunity?
CoreWeave (NASDAQ: CRWV) was one of last year's biggest artificial intelligence (AI) success stories, and the company's revenue strength continues. The cloud player launched its initial public
PayPal Buyout Rumors
In this podcast, Motley Fool contributors Travis Hoium, Lou Whiteman, and Rachel Warren discuss:
To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. When
Trying to Get the $5,251 Max Social Security Benefit Is Overrated. Do This Instead.
Let's be honest: We all want the $5,251 max Social Security benefit. That kind of money, coupled with any personal savings you've managed to scrape together, could give most people a comfortable
Could Investing $10,000 in Circle (CRCL) Stock Make You a Millionaire?
Circle Internet Group (NYSE: CRCL), the issuer of the USD Coin (CRYPTO: USDC) stablecoin, went public last June at $31 per share. Its stock now trades at nearly $94. Could investing $10,000 in this
Why Planet Labs Stock Popped Today
Planet Labs (NYSE: PL) stock jumped 8.6% through 12:15 p.m. ET Monday -- and it's not hard to figure out why.
Over the weekend, war broke out among the United States, Israel, and Iran. Most denizens
Want $1 Million In Retirement? Invest $100 a Month in These 3 Stocks and Don't Look Back.
Building a million-dollar retirement portfolio takes a combination of three things. You need to invest enough money into investments that are generating a high enough return to reach that target by
Unexpected Stock Picks and Looking to the Future
In this podcast, Motley Fool contributors Rick Munarriz, Jason Hall, and Travis Hoium dive into stocks that they are willing to give up their Fool card for. There's also a look at how they think the
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing
Palo Alto Investors LP disclosed an increase of 209,523 shares in Dyne Therapeutics (NASDAQ:DYN) in its 13F filing for the quarter ended December 31, 2025, an estimated $3.97 million trade based on
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing
Palo Alto Investors LP initiated a new position in Compass Therapeutics (NASDAQ:CMPX), buying 2,532,419 shares during the quarter for a position value of $13,599,090 as of December 31, 2025
RadNet (RDNT) Q4 2025 Earnings Call Transcript
Image source: The Motley Fool.
Monday, March 2, 2026 at 10:30 a.m. ET
Need a quote from a Motley Fool analyst? Email [email protected]
Source Fool.com
Kosmos Energy (KOS) Q4 2025 Earnings Transcript
Image source: The Motley Fool.
Monday, Mar. 2, 2026 at 11 a.m. ET
Need a quote from a Motley Fool analyst? Email [email protected]
Source Fool.com
1 Reason I'd Happily Buy Pfizer (PFE) Stock and Never Sell
If you ask me for a reason I'd buy Pfizer (NYSE: PFE) stock and never sell it, I certainly have one -- because I've already bought into Pfizer, and I have no plans to sell it. Here's a look at why I
This ETF Has Delivered Massive Returns for 33 Years -- And It's Just Hitting Its Stride
Many investors don't have the time or inclination to invest in individual stocks. The amount of research needed to keep track of a well-diversified portfolio of 25 stocks or more is considerable
Why Turning Point Brands Stock Is Plummeting Today
Shares of white nicotine pouch and smoking accessories maker and marketer Turning Point Brands (NYSE: TPB) are down 20% as of 11 a.m. ET this morning after the company released fourth-quarter
MercadoLibre Hits $14.5 Billion Sales as New $829 Million Position Surfaces
Eagle Capital Management initiated a new position in MercadoLibre (NASDAQ:MELI), acquiring 411,549 shares in the fourth quarter, according to a February 17, 2026, SEC filing.
According to an SEC
Up Over 400% in 5 Years, Is It Too Late to Invest in Eli Lilly Stock?
Eli Lilly (NYSE: LLY) is the most valuable healthcare company in the world, as its valuation hovers around $1 trillion. It has generated fantastic gains for investors, rising by more than 400% in
Why AbbVie Stock May Be the Ultimate Option for Dividend Investors
Dividend stocks can make for great long-term investments. They can generate a steady stream of income for your portfolio, not only padding your overall returns but also providing you with a way to
Is CRISPR Therapeutics Stock Too Risky to Buy Right Now?
CRISPR Therapeutics (NASDAQ: CRSP) is a company that can potentially help revolutionize healthcare. Its gene-editing therapies can be game changers for patients living with illnesses and conditions